rofecoxib Vioxx withdrawn
Selected indexed studies
- Rofecoxib. (, 2012) [PMID:31643940]
- Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials. (J Intern Med, 2022) [PMID:35585779]
- Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. (J Pharm Pharm Sci, 2013) [PMID:24393558]
_Worker-drafted node — pending editorial review._
Connections
rofecoxib Vioxx withdrawn is a side effect of
Sources
- Rofecoxib. (2012) pubmed
- Rofecoxib for osteoarthritis. (2005) pubmed
- Adverse effects of nonsteroidal antiinflammatory drugs: an update of gastrointestinal, cardiovascular and renal complications. (2013) pubmed
- Lessons from 20 years with COX-2 inhibitors: Importance of dose-response considerations and fair play in comparative trials. (2022) pubmed
- Single dose oral rofecoxib for acute postoperative pain in adults. (2009) pubmed
- Rofecoxib in migraine. (2005) pubmed
- Rofecoxib (Vioxx) voluntarily withdrawn from market. (2004) pubmed
- [Rofecoxib (Vioxx) has been withdrawn, what next?]. (2004) pubmed
- Cyclooxygenase-2 inhibitors. (2005) pubmed
- [Withdrawal of rofecoxib (Vioxx): what about cardiovascular safety of COX-2 selective non-steroidal anti-inflammatory drugs?]. (2004) pubmed